Pleural Effusion, Thoracic Effusion
Conditions
Brief summary
To assess risks of bleeding in those individuals receiving Novel Oral Anti-Coagulant (NOAC) medications, admitted to the hospital and require thoracentesis, chest tube or tunneled pleural catheter placement.
Detailed description
The research component of this study simply observes and documents the outcomes of these procedures. Patients will undergo an analysis of their pre-procedural hematocrit and this will be compared to their post-procedural (next day) hematocrit.
Interventions
DRUGNovel Oral Anti-Coagulants
Novel Oral Anti-Coagulant (NOAC) medications (i.e. Eliquis, Plavix, Xarelto etc.)
Sponsors
Yale University
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age \> 18 y/o 2. Unilateral or bilateral pleural effusion 3. Ability to provide consent or consent given for the procedure and research study
Exclusion criteria
Adults who refuse to provide consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Risk of bleeding | 2 years | Reduced risk of bleeding in individuals receiving Novel Oral Anti-Coagulants as well as those that are in the control group will be assessed by having the patients undergo an analysis of their pre-procedural hematocrit which will be compared to their post procedural (next day) hematocrit |
Countries
United States
Outcome results
None listed